AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for GPI inositol-deacylase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q75T13

UPID:

PGAP1_HUMAN

Alternative names:

Post-GPI attachment to proteins factor 1

Alternative UPACC:

Q75T13; Q4G0R8; Q4ZG47; Q53SM0; Q6AW92; Q6UWV4; Q9HA24

Background:

GPI inositol-deacylase, also known as Post-GPI attachment to proteins factor 1, plays a crucial role in the inositol deacylation of GPI-anchored proteins. This process is vital for the efficient transport of these proteins from the endoplasmic reticulum to the Golgi apparatus. The protein's function underscores its importance in cellular transport mechanisms.

Therapeutic significance:

GPI inositol-deacylase is linked to a neurodevelopmental disorder characterized by dysmorphic features, spasticity, and brain abnormalities. Understanding the role of GPI inositol-deacylase could open doors to potential therapeutic strategies for this disorder, highlighting the protein's significance in medical research.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.